Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022
November 07 2022 - 7:30AM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing a novel form of cognitive
behavioral therapy (CBT) to address the root causes of
cardiometabolic diseases, today announced it will release its third
quarter 2022 financial results after the market closes on Monday,
November 14, 2022. Management will host a conference call and
webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT
on Monday, November 14, 2022.
To access the conference call, please register at:
https://register.vevent.com/register/BI2c729f96a5894042b72aa89ac43ae0c8.
Upon registering, each participant will be provided with call
details and access codes. All participants are encouraged to join
10 minutes prior to the start time. The live webcast may be
accessed by visiting the event link at:
https://edge.media-server.com/mmc/p/uritguso. Following the
webcast, a replay of the webcast may be accessed from the
Presentations & Events page in the Investors section of the
Better Therapeutics corporate website at:
investors.bettertx.com.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy
(CBT) to address the root causes of cardiometabolic diseases. The
company has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The CBT delivered by Better
Therapeutics’ PDT is designed to enable changes in neural pathways
of the brain so lasting changes in behavior become possible.
Addressing the underlying causes of these diseases has the
potential to dramatically improve patient health while lowering
healthcare costs. Better Therapeutics’ clinically validated mobile
applications, if authorized for marketing, are intended to be
prescribed by physicians and reimbursed like traditional
medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005117/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024